GlassScriptPhysician profile
Kam Sing Ho
NPI 1013494194
$2,393.62
in general payments reported to CMS, 2019-2025
17 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $202 · 2023: $319 · 2024: $314 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Education: $74.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.92 |
| Education | $74.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $756.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $517.48 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $377.70 | 2023-2025 | Imfinzi, Tezspire, Fasenra |
| Janssen Pharmaceuticals, INC | $122.18 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $99.38 | 2025 | Dupixent |
| Portola Pharmaceuticals, LLC | $79.66 | 2020 | |
| Insmed, INC. | $67.77 | 2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $66.83 | 2024-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Lilly USA, LLC | $50.14 | 2025 | Zepbound, Mounjaro |
| United Therapeutics Corporation | $40.09 | 2025 | Tyvaso |
| Amgen INC. | $39.27 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $39.02 | 2025 | Glassia |
| Verona Pharma, INC. | $24.13 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $21.52 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $18.85 | 2025 | Hemosphere |
| Viatris Specialty LLC | $16.00 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kam Sing Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.